FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2583505640> ?p ?o ?g. }

• W2583505640 endingPage "3167" @default.
• W2583505640 startingPage "3167" @default.
• W2583505640 abstract "Abstract The genomic landscape of myeloproliferative neoplasms (MPNs) has altered dramatically due to the recent discovery of somatic mutations of calreticulin (CALR). This discovery enables for the first time molecular information, in addition to JAK2V617F, to be used in the majority of MPN patients as an affirmative variable to discriminate MPNs from reactive myeloid proliferations. The clinical course of essential thrombocythemia (ET) or primary myelofibrosis (PMF) in patients carrying the CALR mutation was reported to be more indolent than in JAK2 positive patients and was associated with increased survival. Our aim was to investigate whether the impact of CALR expression on prognosis and clinical outcome is different in prefibrotic/early PMF (prePMF) compared to WHO-ET. In a cohort of 348 adult patients with the clinical diagnosis of either ET or PMF mutational analysis for CALR was available. Eligibility criteria for the study included: availability of mutation analysis for JAK2, MPL and CALR; availability of representative, treatment-naive bone marrow biopsy (BM); availability of a histological and clinical consensus on the diagnosis; complete long-term documentation of clinical data and outcome. Consenting clinico-pathological findings in our cohort were consistent with 115 cases showing WHO-ET and 85 patients with prePMF. In comparison to WHO-ET, prePMF revealed minor/borderline age- and gender-matched anemia, slight increase in serum LDH level and leukocyte count, minor to slight splenomegaly, and an occasional left shift in granulo- and erythropoiesis with occurrence of a few myelo-and/or erythroblasts (table 1). An accurate differentiation between both MPN entities was shown to exert a significant difference in terms of overall and relative survival and hematologic transformation into overt PMF and AL. The present study revealed a different CALR mutation frequency in ET in contrast to most of the investigations published recently. We observed CALR mutations in 18% of WHO-ET; JAK2, MPL and CALR wildtype (wt) was observed in 13% of WHO-ET. The discrepancy in the frequencies of CALR positivity in our ET cohort to most of the recently published studies may be due to our strict adherence to the WHO criteria for diagnosis of ET. Regarding prePMF, we observed CALR mutations in 39% of the patients. 92% of the JAK2 and MPL wt subgroup carried the CALR mutation, with JAK2, MPL and CALR wt being observed in only 3% of prePMF. The most remarkable differences between WHO-ET and prePMF were seen in the comparison of the overall survival (figure 1). While the CALR mutation did not have any beneficial influence on survival in WHO-ET, it was associated with a superior overall survival in prePMF. Such a striking difference was not seen at the time of transformation into overt myelofibrosis, and there was only a slightly shorter time to progression to fibrosis in CALR wt prePMFs. There was a trend showing that CALR mutated prePMF patients have shorter thrombosis-free survival compared to CALR wt prePMF patients. There was no impact of the CALR mutations on thrombosis-free survival in WHO-ET. The present data confirm that WHO-ET and prePMF are biologically different sub-entities of MPNs. In prePMF, almost 100% of patients are now associated with a known disease-causing mutation. Our data support the classical clinical approach in the diagnosis of thrombocytosis, using BM histology to differentiate WHO-ET from prePMF and to estimate the outcome of the disease more accurately. Table 1:Total cohort (N=200)WHO-ET (N=115)prePMF (N=85)PAge at diagnosis, years0,04median58,8556,460,7range19-8819-8427-88Sex0,587male784335female1227250Hb, g/dL<0,001median14,114,313,5range8,1-17,68,8-17,68,1-16,6WBC, x109/l0,054median9,258,999,6range4,01-24,544,92-22,34,01-24,54Platelets, x109/l0,739median770770794range78-2530414-249078-2530Palpable splenomegaly<0,001No.51 (12 unk, 1 splenectomy)16 (7 unk, 1 splenectomy)35 (5 unk)%25,513,941,2Fibrotic transformations<0,001No.24 (10 unk)6 (1 unk)18 (9 unk)%125,221,2Thrombotic events0,439No.39 (1 unk)22 (1 unk)17%19,51920prev thrombosis0,042No.503416%2530,418,8JAK2 V617F pos0,08No.1207545%6065,252,9CALR pos0,001No.542133%2718,338,8MPL pos0,189No.844%43,54,7JAK2/MPL/CALR wt0,0029No.18153%9133,5 Figure 1 Figure 1. Disclosures Thiele: AOP Orphan Pharmaceuticals: Consultancy, Honoraria; Incyte Corporation: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Shire: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria." @default.
• W2583505640 created "2017-02-10" @default.
• W2583505640 creator A5003768458 @default.
• W2583505640 creator A5007091163 @default.
• W2583505640 creator A5009431793 @default.
• W2583505640 creator A5030951829 @default.
• W2583505640 creator A5033256307 @default.
• W2583505640 creator A5036871832 @default.
• W2583505640 creator A5049331182 @default.
• W2583505640 creator A5052112147 @default.
• W2583505640 creator A5058120698 @default.
• W2583505640 creator A5060982659 @default.
• W2583505640 creator A5064978902 @default.
• W2583505640 creator A5073807974 @default.
• W2583505640 creator A5090641063 @default.
• W2583505640 date "2014-12-06" @default.
• W2583505640 modified "2023-10-01" @default.
• W2583505640 title "Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia" @default.
• W2583505640 doi "https://doi.org/10.1182/blood.v124.21.3167.3167" @default.
• W2583505640 hasPublicationYear "2014" @default.
• W2583505640 type Work @default.
• W2583505640 sameAs 2583505640 @default.
• W2583505640 citedByCount "0" @default.
• W2583505640 crossrefType "journal-article" @default.
• W2583505640 hasAuthorship W2583505640A5003768458 @default.
• W2583505640 hasAuthorship W2583505640A5007091163 @default.
• W2583505640 hasAuthorship W2583505640A5009431793 @default.
• W2583505640 hasAuthorship W2583505640A5030951829 @default.
• W2583505640 hasAuthorship W2583505640A5033256307 @default.
• W2583505640 hasAuthorship W2583505640A5036871832 @default.
• W2583505640 hasAuthorship W2583505640A5049331182 @default.
• W2583505640 hasAuthorship W2583505640A5052112147 @default.
• W2583505640 hasAuthorship W2583505640A5058120698 @default.
• W2583505640 hasAuthorship W2583505640A5060982659 @default.
• W2583505640 hasAuthorship W2583505640A5064978902 @default.
• W2583505640 hasAuthorship W2583505640A5073807974 @default.
• W2583505640 hasAuthorship W2583505640A5090641063 @default.
• W2583505640 hasConcept C126322002 @default.
• W2583505640 hasConcept C143998085 @default.
• W2583505640 hasConcept C158617107 @default.
• W2583505640 hasConcept C2778837598 @default.
• W2583505640 hasConcept C2779282312 @default.
• W2583505640 hasConcept C2780007613 @default.
• W2583505640 hasConcept C2780076729 @default.
• W2583505640 hasConcept C2781057849 @default.
• W2583505640 hasConcept C2781107747 @default.
• W2583505640 hasConcept C47450691 @default.
• W2583505640 hasConcept C54355233 @default.
• W2583505640 hasConcept C71924100 @default.
• W2583505640 hasConcept C72563966 @default.
• W2583505640 hasConcept C86803240 @default.
• W2583505640 hasConcept C90924648 @default.
• W2583505640 hasConceptScore W2583505640C126322002 @default.
• W2583505640 hasConceptScore W2583505640C143998085 @default.
• W2583505640 hasConceptScore W2583505640C158617107 @default.
• W2583505640 hasConceptScore W2583505640C2778837598 @default.
• W2583505640 hasConceptScore W2583505640C2779282312 @default.
• W2583505640 hasConceptScore W2583505640C2780007613 @default.
• W2583505640 hasConceptScore W2583505640C2780076729 @default.
• W2583505640 hasConceptScore W2583505640C2781057849 @default.
• W2583505640 hasConceptScore W2583505640C2781107747 @default.
• W2583505640 hasConceptScore W2583505640C47450691 @default.
• W2583505640 hasConceptScore W2583505640C54355233 @default.
• W2583505640 hasConceptScore W2583505640C71924100 @default.
• W2583505640 hasConceptScore W2583505640C72563966 @default.
• W2583505640 hasConceptScore W2583505640C86803240 @default.
• W2583505640 hasConceptScore W2583505640C90924648 @default.
• W2583505640 hasIssue "21" @default.
• W2583505640 hasLocation W25835056401 @default.
• W2583505640 hasOpenAccess W2583505640 @default.
• W2583505640 hasPrimaryLocation W25835056401 @default.
• W2583505640 hasRelatedWork W2462502797 @default.
• W2583505640 hasRelatedWork W2524885655 @default.
• W2583505640 hasRelatedWork W2768900384 @default.
• W2583505640 hasRelatedWork W2799932402 @default.
• W2583505640 hasRelatedWork W2903749170 @default.
• W2583505640 hasRelatedWork W2948981975 @default.
• W2583505640 hasRelatedWork W2982450219 @default.
• W2583505640 hasRelatedWork W3013799485 @default.
• W2583505640 hasRelatedWork W3081450346 @default.
• W2583505640 hasRelatedWork W3088387990 @default.
• W2583505640 hasVolume "124" @default.
• W2583505640 isParatext "false" @default.
• W2583505640 isRetracted "false" @default.
• W2583505640 magId "2583505640" @default.
• W2583505640 workType "article" @default.